TMO
NYSE · Healthcare · Medical - Diagnostics & Research · US
Research · Sep 3, 2026
[TMO] Thermo Fisher Thesis 2026: Biopharma End-Market Recovery + Olink Proteomics Test Platform Re-Acceleration
Thermo Fisher FY2025 revenue ~$43.5B (+3-5% YoY) with adj. operating margin ~22.5% — third year navigating COVID revenue wind-down ($7B FY2021 peak → $1B FY2025) while underlying biopharma services + life sciences tools recover. Laboratory Products & Biopharma Services ~$22B (largest segment) — integrated PPD CRO + Patheon CDMO + Fisher Scientific platform serves biopharmaceutical customers end-to-end. FY2026 thesis: biopharma capex/clinical trial spending re-accelerates on GLP-1 expansion + gene therapy commercialization + biosimilar launches; Olink (proteomics, $3.1B acquisition Aug 2024) scales as proteomics adoption accelerates; PPD margin expansion through synergy capture; key risks: biopharma funding constraint extends, China research market deterioration, NIH budget pressures.
Research · Aug 25, 2026
Plasma Proteomics Shifts From Plex Count to Cross-Platform Accuracy
Independent cross-platform data now ranks plasma proteomics platforms: Seer cites 13.5% of its targets unlikely to concur, against 39% and over 45% for rivals.
Research · Apr 13, 2026
Trump 100% Pharma Tariffs: PFE and MRK Face $200M Hit While LLY Gains 25%
Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.
Research · Apr 9, 2026
Pharma Tariffs: LLY, TMO, CVS Supply Chain Exposure Ranked by Risk
Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.